Core Insights - NORBIT reported Q1 2025 revenues of NOK 521.7 million, a 29% increase from Q1 2024, with an EBIT of NOK 127.4 million and a margin of 24% [1] - Diluted earnings per share rose to NOK 1.40 from NOK 0.50 year-over-year [1] - The company is optimistic about its 2025 revenue target of NOK 2.2 – 2.3 billion, expecting an improved EBIT margin compared to the previous year's 20% [3] Business Segments Performance - The Oceans segment achieved revenues of NOK 232.7 million, a 92% increase from Q1 2024, with an EBIT margin of 35% [7] - The Connectivity segment reported revenues of NOK 145.9 million, consistent with Q1 2024, and an EBIT margin of 28% [7] - The Product Innovation & Realization segment saw an 11% revenue growth to NOK 160.6 million, with an EBIT margin of 14% [7] Strategic Positioning - NORBIT emphasizes its market-driven innovation and strong operational foundation to meet growing demand across all business segments [2] - The company is focused on strategic investments in capacity and competence to capitalize on growth opportunities [2] - NORBIT operates in three key segments: Oceans, Connectivity, and Product Innovation & Realization, addressing specific market needs [4]

Group 1 - The company reported a solid start to the year with group turnover reaching 993 million euros, reflecting a 10% increase compared to 900 million euros a year ago [3] - The order book remains healthy at 7.6 billion euros, slightly up from 7.5 billion euros a year ago, excluding the order book from Havfram [3] - Management has reaffirmed guidance for the year, expecting turnover and EBITDA margin to be at least in line with last year's performance [3] Group 2 - Subsequent to the quarter end, the company acquired Havfram, a Norwegian offshore wind contractor, which supports its ambition to expand in the offshore wind energy market [3] - The acquisition is expected to bolster the company's competitive edge in turbine and foundation installations [3]

Core Viewpoint - Bekaert is navigating challenging market conditions due to tariffs and trade tensions, successfully passing on costs to customers while maintaining a strong balance sheet and stable sales expectations for 2025 [1][5]. Financial Highlights - Q1 2025 consolidated sales were €991 million, a decrease of 3% compared to Q1 2024, driven by a 1% decline in like-for-like volumes (€12 million), a 1% reduction from price-mix (€11 million), and a 2% pricing impact from lower input costs (€23 million) [4]. - Sales from joint ventures (non-consolidated) amounted to €214 million, down 2% from Q1 2024 [4]. - A proposed dividend of €1.90 per share at the AGM and an ongoing two-year €200 million share buyback program, with approximately €50 million purchased to date [4]. Operational and Strategic Highlights - The company has been able to mitigate tariff impacts through local sourcing and production, with minimal financial impact from tariffs to date [1][5]. - The Rubber Reinforcement segment showed strong performance in China, offsetting volume decreases in Europe and North America, while the Steel Wire Solutions segment reported solid sales performance [4]. - Specialty Businesses faced project delays in flooring in North America, but adoption is accelerating in growth markets [4]. Tariff Impacts - The introduction of tariffs has created significant uncertainty, leading to delayed orders and investment decisions from customers, particularly in the construction segment [2]. - The long-term effects of tariffs on end market demand and trade flows remain uncertain and could be material [2]. Outlook - The difficult market conditions from the second half of 2024 are expected to persist into Q1 2025, with ongoing uncertainty around tariffs and the global macroeconomic outlook [3]. - The company anticipates stable sales and EBIT margins for the full year 2025 compared to 2024, with a more balanced performance expected between the first and second halves of the year [5].

Group 1 - Mowi ASA's Annual General Meeting is scheduled for June 4, 2025, at 11:00 CET and will be conducted as a digital meeting [1] - The notice for the meeting, including the agenda and selected appendices, has been sent to all shareholders [1] - Complete appendices will be available on Mowi's investor website [1]

Core Insights - Mowi reported revenues of €1.36 billion (NOK 15.8 billion) and an operational EBIT of €214 million (NOK 2.5 billion) for Q1 2025, showing increased revenues and results compared to the same quarter last year due to strong biological and operational performance, higher volumes, and lower costs [1][2] Financial Performance - The company experienced a 12% increase in slaughter volumes, totaling 108,000 tons in the quarter compared to last year, and maintains a volume guidance of 530,000 tons for 2025, which represents an annual growth of 6% [3] - Mowi's production in the sea showed improved growth, survival rates, feed conversion ratios, and quality, with an expected annual growth of 5.1% by the end of the year, compared to the industry average of 3.3% [4] Market Demand and Supply - Demand for salmon was strong across Europe, America, and Asia, although prices were under pressure due to high supply growth, which was 13% in Europe and 8% globally in Q1 [5][6] - Mowi expects supply growth to normalize to 2-3% next year due to regulatory constraints after an anticipated 6% growth for the year [6] Strategic Developments - Mowi's recent acquisition of an increased ownership stake in Nova Sea from 49% to 95% is expected to boost slaughter volumes to 600,000 tons next year [3] - The company’s feed production segment, Mowi Feed, also reported record volumes and earnings for the first quarter, contributing significantly to the growth in slaughter volumes [6][7] Dividend Announcement - The board of Mowi has decided on a dividend of NOK 1.70 per share for the first quarter [7] Company Overview - Mowi is one of the world's leading seafood companies and the largest producer of Atlantic salmon, with an estimated slaughter volume of 530,000 tons in 2025 from seven farming countries [8][9]

Core Insights - Mowi reported operating revenues of EUR 1.36 billion and an operational profit of EUR 214 million in Q1 2025, showing an increase compared to the same quarter last year due to strong biological and operational performance [1][2] - The company harvested 108,000 tonnes in Q1 2025, a 12% increase year-on-year, and maintains a harvest volume guidance of 530,000 tonnes for the year, projecting a 6% annual growth [3][5] - Mowi's feed segment also performed well, contributing to the overall growth in harvest volumes, with record-high earnings and sold volumes for the first quarter [7][8] Financial Performance - Mowi's operational profit of EUR 214 million reflects strong performance driven by high harvest volumes and improved cost management [1] - The company plans to pay a quarterly dividend of NOK 1.70 per share, indicating confidence in its financial health [8] Market Dynamics - Global supply growth in Q1 2025 was 13% in Europe and 8% globally, attributed to a one-off correction after three years of challenging biological conditions [6][7] - Demand for salmon remained strong across Europe, the Americas, and Asia, although high supply growth has put pressure on market prices [6] Strategic Initiatives - Mowi's strategic focus on volume growth across the value chain is evident, with a projected increase in harvest volumes from 375,000 tonnes in 2018 to 600,000 tonnes by the end of 2026, representing a CAGR of 5.1% [5] - The company has increased its ownership of Nova Sea from 49% to 95%, which is expected to further enhance its harvest capacity [3]

Core Points - The 2025 Fujian Global Innovation and Entrepreneurship Competition aims to attract overseas professionals and promote strategic emerging industries in Fujian [1][4] - The competition features cash awards totaling 150,000 yuan for first prizes, 100,000 yuan for second prizes, and 50,000 yuan for third prizes, with additional excellent awards of 20,000 yuan [2] - Participants will compete in three categories: digital economy, biotechnology, and advanced manufacturing, showcasing innovations in artificial intelligence, biomedicine, new energy, and new materials [2] Competition Structure - The competition consists of four stages: registration, review process, preliminary round, and final round, with registration open from May 10 to July 10, 2025 [3] - The preliminary round will occur online in July, followed by offline pitch presentations in early September during the China International Fair for Investment & Trade (CIFIT) [3] - An awards ceremony will conclude the competition, accompanied by industry tours and investor networking sessions [3] Support for Participants - First-prize winners can receive recognition as Category B High-Level Talent, with a settlement subsidy of up to 1 million yuan [4] - Second- and third-prize winners can be recognized as Category C High-Level Talent, eligible for a settlement subsidy of up to 500,000 yuan [4] - Projects may qualify for the Hundred Talents Program for Entrepreneurship, with potential subsidies of up to 2 million yuan [4]

Core Insights - Prairie Provident Resources Inc. reported strong production results from its three-well Basal Quartz horizontal drilling program in the Michichi area of Central Alberta during Q1 2025, with all wells now in production [1][2]. Production Results - The three BQ horizontal wells were drilled and completed within budget, showcasing the high-quality geological characteristics of the Michichi BQ play [2]. - Initial production rates for the three wells are as follows: - Well 100/14-32-029-18W4: Peak oil rate of 357 bbl/d, IP30 of 275 bbl/d [3]. - Well 102/13-32-029-18W4: Peak oil rate of 367 bbl/d, IP21 of 328 bbl/d [3]. - Well 100/07-19-030-18W4: Peak oil rate of 585 bbl/d, IP21 of 389 bbl/d [3]. - Total company sales production for the first week of May 2025 averaged 3,467 boe/d, with 1,567 boe/d coming from the three BQ wells [3]. Financial Highlights - For Q1 2025, Prairie Provident reported petroleum and natural gas sales of $11.073 million, with a net revenue of $9.601 million after royalties [6]. - The company experienced a net loss of $6.137 million in Q1 2025, which is an increase from a net loss of $4.945 million in Q1 2024 [6][8]. - Adjusted funds flow for Q1 2025 was $1.782 million, a significant recovery from a negative flow in Q4 2024 [6][8]. Operational Efficiency - Operating expenses for Q1 2025 were $29.64 per boe, a decrease of 17% from Q1 2024, attributed to the sale of higher-cost properties [8]. - Operating netback before derivatives was $3.7 million ($18.38/boe), reflecting a 74% increase compared to Q1 2024 [8]. Future Development Potential - Prairie Provident has identified over 40 potential drilling opportunities targeting medium crude oil on its Michichi lands, supported by existing infrastructure and seismic data [4]. - The company completed a brokered equity financing in early 2025, raising $8.67 million to facilitate further development in the BQ formation [8].

Core Insights - PyroGenesis Inc. reported its financial and operational results for Q1 2025, highlighting a revenue of $3 million, a 14% decrease compared to Q1 2024, but an improvement in gross margin to 27% from 21.7% in the previous year [7][17][25]. Financial Highlights - Revenue for Q1 2025 was $3 million, down from $3.5 million in Q1 2024 [7][17]. - Gross margin improved to 27%, a 5.3-point increase from the previous year's 21.7% [7][25]. - Net loss for Q1 2025 was $4.26 million, slightly better than the loss of $4.4 million in Q1 2024 [7][37]. - Revenue backlog as of May 13, 2025, stood at $52 million, with 88% in U.S. dollars [7][19]. Operational Highlights - The company is focused on cost optimization, targeting an additional $3 to $5 million in recurring savings for 2025, building on over $3 million in savings achieved in 2024 [3][58]. - The company operates in three main business verticals: Energy Transition & Emission Reduction, Commodity Security & Optimization, and Waste Remediation [6][8]. Business Developments - Significant contracts include a $2.5 million agreement with a major environmental services company for gas flaring components and a $2.4 million contract with Norsk Hydro for plasma torches in aluminum production [10][12]. - The company is advancing in the production of fumed silica and has successfully produced the first batch from its pilot plant [82][83]. - Ongoing discussions for potential contracts in waste remediation and plasma-based glass valorization are in the final negotiation stages, with estimated values of $2 million and $2-3 million respectively [85][87][88]. Strategic Outlook - The company is well-positioned for future growth due to a strong project backlog and ongoing collaborations in energy transition initiatives [2][41]. - The focus on electrification and carbon reduction aligns with broader industry trends and government support for environmental technologies [44][46]. - The company aims to enhance its market presence by attracting influential customers across various industries, including aluminum, steelmaking, and chemicals [47][56].

Core Viewpoint - Belite Bio, Inc is advancing its clinical development of Tinlarebant, targeting degenerative retinal diseases, with positive interim results from the Phase 3 DRAGON trial and plans for trial completion by the end of 2025 [2][4]. Clinical Highlights - Tinlarebant is an oral, once-daily RBP4 antagonist that reduces RBP4 levels in the blood, decreasing vitamin A delivery to the eye, which is crucial for normal vision but can lead to toxicity in certain retinal diseases [3]. - The independent Data Safety Monitoring Board (DSMB) recommended the continuation of the DRAGON trial without modifications, with completion expected in Q4 2025 [4]. - The ongoing Phase 3 trial (PHOENIX) for Tinlarebant in geographic atrophy (GA) patients has enrolled 464 out of the targeted 500 subjects [4][14]. Financial Highlights - As of March 31, 2025, the company reported current assets of $157.4 million, including cash and liquidity funds [7]. - Research and development expenses for Q1 2025 were $9.4 million, up from $6.8 million in Q1 2024, primarily due to increased share-based compensation and clinical trial expenses [8]. - General and administrative expenses rose to $6.1 million in Q1 2025 from $1.6 million in Q1 2024, attributed to share-based compensation [9]. - The company reported a net loss of $14.3 million for Q1 2025, compared to a net loss of $7.9 million in the same period of 2024 [11][17]. Corporate Highlights - In February 2025, Belite Bio raised $15 million in gross proceeds through a registered direct offering, with potential additional proceeds from warrant exercises [6]. - The company is focused on maintaining strong execution across its late-stage clinical programs to deliver new treatment options for degenerative retinal diseases [2]. Upcoming Milestones - A conference call and webcast is scheduled for May 14, 2025, to discuss financial results and provide a business update [12]. - The primary efficacy endpoint for the DRAGON trial is the growth rate of atrophic lesions, with safety and tolerability also being assessed [5][14].